We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 27.50 | 1.59% | 1,761.00 | 1,757.50 | 1,758.00 | 1,767.00 | 1,736.00 | 1,736.00 | 14,302,622 | 16:35:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.69 | 72.38B |
From May 2021 to May 2024
By Michael Dabaie
GlaxoSmithKline PLC and Vir Biotechnology Inc. said the U.S. government will purchase an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the early treatment of Covid-19.
The companies said the additional 600,000 doses would be delivered throughout the first quarter of 2022. The agreement is an amendment to earlier commitments unveiled with the U.S. government in November 2021.
GSK and Vir said they have received binding agreements for the sale of about 1.7 million doses of sotrovimab worldwide.
Tuesday's agreement also includes the option for the U.S. government to purchase further additional doses in the second quarter of 2022.
Sotrovimab, which was granted emergency use authorization by the U.S. Food and Drug Administration in May, is an investigational single-dose intravenous infusion SARS-CoV-2 monoclonal antibody.
Under the EUA, sotrovimab can be used for the treatment of mild-to-moderate Covid-19 in adults and pediatric patients 12 and older.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 11, 2022 07:55 ET (12:55 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
